The metastatic colorectal cancer market is growing with progress in targeted therapies, immunotherapies, and precision diagnostics. Leading companies, including Merck, Amgen, and F. Hoffmann-La Roche, are advancing new treatments and biomarker-driven approaches. Rising disease incidence, wider screening initiatives, and demand for personalized care are fueling expansion, while continued innovation focuses on improving survival and patient quality of life. Access Market Report: https://shorturl.at/d8MXe